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Design characteristics of the CORRONA CERTAIN
study: a comparative effectiveness study of
biologic agents for rheumatoid arthritis patients
Dimitrios A Pappas1,2, Joel M Kremer3, George Reed2,4, Jeffrey D Greenberg2,5 and Jeffrey R Curtis6*
Abstract
Background: Comparative effectiveness research has recently attracted considerable attention. The Comparative
Effectiveness Registry to study Therapies for Arthritis and Inflammatory Conditions (CERTAIN) is an ongoing
prospective cohort study of adult patients with Rheumatoid Arthritis (RA).
Methods/Design: CERTAIN uses the existing Consortium of Rheumatology Researchers of North America
(CORRONA) network of participating private and academic sites in order to recruit patients fulfilling the 1987 ACR
criteria that have at least moderate disease activity. Patients starting or switching biologic agents either anti-TNF
therapy or a non anti-TNF biologic are eligible for enrollment, depending on the treatment selected by their
physician. Enrollment is expected to be completed by March of 2014, and 2711 patients will participate in the study.
As of October 7th 2013, 2234 patients have been enrolled. Patient visits and laboratory blood work are mandated
every three months for one year. Safety data is collected through one year and beyond. The primary comparative
effectiveness endpoint is attainment of low RA disease activity at one year among patients who have been exposed
to at least one prior TNF-α inhibitor agent prior to enrollment. Multiple secondary effectiveness and safety endpoints
will be addressed by investigating the entire population enrolled (naïve and biologic experienced).
Discussion: The unique design features of CERTAIN will inform comparative effectiveness and safety questions for
choosing biologic agents for the management of RA.
Keywords: Rheumatoid arthritis, Registry, Cohort, Epidemiology, Comparative effectiveness, Safety, Biologics
Background
Considerable attention and funding has recently been al-
located to comparative effectiveness research (CER). In
the U.S., for example, the American Recovery and Re-
investment Act (ARRA) devoted approximately 1 billion
dollars in support of such studies in 2009 [1].
According to the Institute of Medicine, “The purpose
of CER is to assist consumers, clinicians, purchasers,
and policy makers to make informed decisions that will
improve health care at both the individual and popula-
tion levels” [2]. CER cannot only compare existing ther-
apies in widespread use but also has the potential to
establish standards and a mechanism by which newly
available medications can be evaluated and compared to
standard therapies. It may facilitate the creation of a
more demanding scientific and medical community cul-
ture by which promotion of innovation in drug discovery
will be encouraged, as opposed to the production of
cloned “me too” therapeutics lacking robust evidence of
superiority against existing medications [2].
Biologic agents in rheumatoid arthritis and the need for
CER in rheumatology
Biologic agents have revolutionized the treatment of
rheumatoid arthritis (RA) over the last decade. Their ef-
ficacy and safety has been clearly demonstrated in the
setting of a multitude of randomized controlled trials
(RCTs). Results for each agent are broadly comparable
across all outcome domains including ACR (American
College of Rheumatology) and EULAR (EUropean
League Against Rheumatism) responses, improvement in
quality of life, and arrest or reversal of radiologic damage
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[3-5]. With the approval of 2 additional TNF inhibitors
(golimumab and certolizumab) and an IL-6 receptor in-
hibitor (tocilizumab) the current therapeutic armament-
arium contains 9 biologic agents for the treatment of
patients with inflammatory arthritis. However, these
medications were studied and approved against com-
parator arms containing placebo, which may not have
significant relevance to clinical practice. Despite regula-
tory requirements for drug approval, showing that a bio-
logic agent is better than placebo does not provide a
relevant context with which to choose among the avail-
able treatment options for RA patients.
Moreover, the magnitude of benefit of biologic agents
in typical RA patients seen in every day practice – as op-
posed to clinical trial participants – has been less clearly
demonstrated, especially for patients with mild or mod-
erate RA disease activity or those with high burdens of
medical comorbidities. These individuals would gener-
ally not qualify to participate in a clinical trial; indeed,
only a minority of patients seen in clinical practice
would qualify for a clinical trial [6-9].
Similar limitations in generalizability, and in under-
standing long term safety, are not available for industry-
conducted head-to-head randomized control trials (RCT)
comparing biologics, especially among patients with prior
biologic exposure.
Lastly, the estimated per person cost of a typical biologic
agent ranges between $15,000-22,000 per year, or more
[10,11]. While this may be justified by the extent of clinical
benefit they offer to patients, the evidence from CER stud-
ies could be used to better inform cost-effectiveness con-
siderations regarding the use of biologics in RA. The
perception that all biologics “are overall the same” may be
contributing to keeping cost high and at roughly compar-
able levels. As an example of prior comparative effective-
ness research that has impacted clinical practice, it is now
known that the first line anti-hypertensive treatment can
be an inexpensive but effective thiazide diuretic instead of
a more costly angiotensin converting enzyme inhibitor. If
not for the ALLHAT study –the landmark CER study
which demonstrated this outcome- it is rather doubtful
that the prescribing habits of internists treating hyperten-
sion would have been altered to promote greater use of
the less costly treatment option [2,12].
The CORRONA network and registry. Mission, history,
governance and funding
The Consortium of Rheumatology Researchers of North
America (CORRONA) was founded in 2001. The COR-
RONA registry collects longitudinal, “real-world” data from
patients and their treating physicians. At the time of this
writing, data on 45,229 patients with rheumatologist-
diagnosed inflammatory arthritis, including 38,776 patients
with RA, have been collected. The CORRONA participating
site network is comprised of more than 100 private and aca-
demic practices across 42 states within the United States,
with more than 350 rheumatologists contributing data. All
geographic regions in the continental United States are rep-
resented and there are no age, racial, disease activity or other
restrictions to patient participation in the registry. As of
October 7th 2013, CORRONA’s database included informa-
tion about 290,020 patient visits, 119,955 patient years of
follow-up observation time, with a mean time of patient fol-
low up of 3.4 years (median 2.6 years).
At each CORRONA registry visit patients and physi-
cians record data on disease severity and activity, RA and
other medications, adverse events, quality of life, selected
laboratory and imaging results, and socio-demographic
information.
By way of providing a brief review of CORRONA’s his-
tory, an independent database collecting data from both
rheumatologists and patients with inflammatory arthritis
did not exist in the US at the time the organization was
founded, and CORRONA aspired to fill this gap. A group
of experienced academic and private rheumatologists
founded and now serve on CORRONA’s board of directors
which is entirely responsible for its governance and its sci-
entific oversight. Operational needs are covered with fund-
ing predominantly derived from the pharmaceutical
industry which may submit queries for data analysis but
does not have access to CORRONA’s raw data. Instead all
queries are evaluated and analyses are performed by
academic-based biostatisticians and epidemiologists. Query
results are generated and provided as summary reports to
the requesting pharma company [13]. Pharmaceutical
companies may submit an abstract or manuscript from the
obtained data, but must follow CORRONA’s publication
and authorship policies. A CORRONA investigator serves
as the lead author, and has final authority on all elements
of the published work.
CORRONA’s successes are exemplified by its contribu-
tion of multiple publications [7-21] in high-yield scientific
journals. To date, CORRONA has collected data at office
visits, as often as every 3 months unless a biologic agent is
started, in which case more frequent data collection is al-
lowable. For routine care in the absence of a change of
these drugs, visits have occurred at a mean interval of
4.5 months. Unlike in CERTAIN, the CORRONA core
registry does not mandate specific laboratory values, and
thus the labs collected by the CORRONA registry reflect
what is felt to be appropriate by the treating rheumatologist
in the course of routine clinical care. Thus, certain values
such as acute phase reactants are sometimes absent.
The Comparative Effectiveness Registry to study Therapies
for Arthritis and Inflammatory Conditions (CERTAIN)
In an attempt to expand the scope of clinical data, and
to focus the scientific yield on comparative effectiveness,
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CORRONA launched the CERTAIN study in late 2010.
CERTAIN is a prospective, non-randomized cohort
study of adult patients with RA fulfilling the 1987 ACR
criteria, having at least moderate disease activity defined
by a clinical disease activity index (CDAI) score >10 who
are starting or switching biologic agents [22]. As of
October 7th 2013, 2234 patients were enrolled across
43 participating academic and private rheumatology
practices.
Methods/Design
The CERTAIN Sub-study has been designed to system-
atically collect and compare the effectiveness and safety
of biologic medications (i.e. anti-TNF therapy, abatacept,
rituximab, tocilizumab). The decision to recruit a patient
into CERTAIN is made during a routine patient visit
when a treating rheumatologist determines that a bio-
logic agent for RA should be started. Even though the
primary endpoint is to investigate comparative effective-
ness among patients who have been exposed to at least
one TNF-α inhibitor, CERTAIN will also enroll naïve to
biologic agents patients in order to address multiple
additional secondary endpoints and inform comparative
safety research. For these secondary analyses of biologic-
naïve patients, and in contrast to the main hypothesis to
be examined by CERTAIN, it is likely that the anti-TNF
and non anti-TNF groups would not be directly com-
pared to one another given the anticipated small num-
bers and substantial heterogeneity in biologic-naïve
patients initiating non anti-TNF therapy. Patients who
initiate non anti-TNF agents as a first line biologic might
be expected to have comorbidities (e.g. heart failure,
cancer) that would make them dissimilar to new anti-
TNF users.
Patients must fulfill the 1987 ACR criteria for RA and
have moderate disease activity (i.e. CDAI > 10) in order
to be eligible for participation. All existing or new COR-
RONA patients will be given the opportunity to partici-
pate. The first visit functions as the screening visit,
during which patient’s consent is obtained and the
process of insurance approval for the biologic to be
started is initiated. After insurance approval is obtained,
the patient returns for a baseline visit, and then for man-
dated follow up visits every three months through 1 year
(i.e. baseline and 3,6,9,12 months follow up visits). Thus,
the visit schedule of CERTAIN mimics that of an open-
label controlled trial (RCT) with required follow visits at
3 month intervals. All biologic agents prescribed are ap-
proved by the Food and Drug Administration and the
choice of which biologic to be initiated is entirely at the
discretion of the prescribing physician.
The full set of data collected by the CORRONA regis-
try are collected at each CERTAIN visit and in addition,
mandated laboratory tests are performed, as indicated in
Table 1. In addition, patients are requested to provide a
sample of blood for DNA extraction and genotyping for
future pharmacogenetics research. Whole blood for gene
expression studies, as well as serum and plasma, is
stored for future biomarker studies. All blood samples
are shipped directly from the participating sites on the
day of blood draw to a central laboratory where analyses
are performed. The patients are reimbursed for their in-
convenience, and physicians are provided with the re-
sults of some of the clinical lab tests at no cost to the
patients or their insurance in order to facilitate clinical
care and avoid redundant testing and phlebotomy.
Quality assurance and quality control procedures for data
collection
Investigators and staff at the 43 academic and private
practices participating in CERTAIN completed a com-
prehensive online and on-site training on the study
protocol prior to study initiation. The training materials
were prepared and delivered by CORRONA personnel
and were tailored to individuals’ roles (e.g. investigators,
research coordinator). Ongoing quality control processes
are in place to ensure high quality and rigorous data col-
lection, overseen by a dedicated team. Study data are
monitored via regular in-person site visits in order to
ensure completeness and accuracy and to help sites re-
solve open queries.
Recruitment targets and ratios
CERTAIN is intended to focus on comparative effective-
ness of established and newly approved biologic treat-
ments for RA for patients who have failed to therapy
with at least one TNF-α inhibitor prior to enrollment.
Given the well-characterized profile of existing bio-
logics for RA, uptake of newer RA treatments is some-
times slow. For that reason, and to maximize statistical
power for comparative analyses, CERTAIN established a
goal to recruit anti-TNF and non anti-TNF therapies in
an approximately 1:1 ratio. Perturbation of this ratio in
up to a 3:2 ratio (in either direction) at each study site is
permissible. In the case of exceeding the enrollment ra-
tio, sites with extreme perturbations beyond the 3:2 limit
will be instructed to temporarily not enroll patients
starting biologics in the study arm in excess.
Individual agents within the anti-TNF and non anti-
TNF categories are not differentiated in the primary ana-
lysis, nor are treatments within each category mandated.
Treatment selection is fully under the control of the
physician and patients are not randomized. The decision
to not randomize patients was made in light of a dearth
of evidence regarding the optimal treatment strategy for
patients who fail one or more anti-TNF inhibitors. Given
this state of relative equipoise in the decision to switch
to another anti-TNF agent or to change to a biologic
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with a different mechanism of action, confounding in the
form of channeling patients to specific medications is likely
to be less problematic than comparisons of biologics vs.
non-biologic DMARDs. Patients who do not qualify for
CERTAIN based upon disease activity criteria or the enroll-
ment ratio are recruited to the CORRONA “core” registry.
In order to reflect a ‘real world’ effectiveness setting,
patients are permitted to change or discontinue biologic
therapies at their physician’s discretion. If they start a
new biologic, however, this action requires a new study
visit at that time. This new study visit (i.e. an ‘early ter-
mination’ visit) ends follow-up time for the first drug
and can define a new screening visit for the next biologic
if the physician and patient so chooses. Patients are
allowed to contribute multiple sets of observations if
they initiate different biologics over the study period; if
they do so, a new ‘baseline’ visit is established. Partici-
pants will continue to be followed longitudinally in the
CORRRONA ‘core’ registry protocol after the comple-
tion of the one-year CERTAIN study. This important
feature allows for long term follow-up for safety and ef-
fectiveness. The above are summarized in Figure 1.
Primary endpoint and covariates of interest
The primary endpoint of CERTAIN is attainment of low
disease activity (LDA) one year after starting or switch-
ing biologic agents and will be assessed only among pa-
tients who have previously been treated with one or
more anti-TNF-α therapies. Patients who are biologic
naïve at enrollment will contribute data to secondary
analyses. LDA is defined as a CDAI ≤ 10. Although en-
rollment criteria and LDA could be defined using
DAS28 (disease activity score using 28 joint counts), the
DAS28 requires knowing the value of the acute phase
reactant result in real time, which is generally not feas-
ible. For that reason, the CDAI was chosen as the RA
disease criterion for enrollment and primary outcome
measure, given the high correlation between CDAI and
DAS28 [22]. Using a dichotomous outcome (response vs
non response) for the primary outcome has limitations,
and any single threshold for considering a patient to be
a ‘responder’ is arbitrary. However, LDA was chosen to
reflect a clinically meaningful endpoint that would likely
result in a patient continuing on that therapy. Thus,
LDA is considered as a proxy outcome for a ‘responder’.
Table 1 Clinical and laboratory assessments during CERTAIN
Baseline Follow up visits
0 Months 3, 6, 9, 12 Months
Assessments
Demographics (date of birth, sex, address, email) X
Medication exposures (including biologics) X X
Tender & Swollen Joint Count (0–28) X X
Physician Global Disease Activity (100 mm VAS) X X
Patient Global Disease Activity (100 mm VAS) X X
Patient Pain (100 mm VAS) X X
Patient Fatigue (100 mm VAS) X X
EuroQol 5D X X
HAQ DI X X
Laboratory assessments (run at a central laboratory)
Complete blood count (with automated differential) X X
Rheumatoid factor and isotypes X
Anti- cyclic citrullinated peptide antibody X
High-sensitivity C–reactive protein (hsCRP) X X
Immunoglobulin panel (IgM, IgG, IgA) X X
Traditional non fasting lipoprotein analyses (HDL, Total cholesterol, Triglycerides) X X
Direct quantitative LDL (fasting specimens not required) X X
Serum, plasma, whole blood (RNA) X X*
AST ALT, Albumin, Total and direct Bilirubin, BUN, Creatinine, Glucose, Calcium, Serum uric acid, CK, LDH X X
DNA (optional component) X
Abbreviations: VAS visual analog scale, CRP C-reactive protein, HAQ health assessment questionnaire, DI disability index, HDL high density lipoprotein, LDL low
density lipoprotein, RNA ribonucleic acid, AST aspartate aminotransferase, ALT alanine aminotransferase, BUN blood urean nitrogen, CK creatinine kinase,
LDH lactate dehydrogenase, DNA deoxyribonucleic acid.
*Collected at baseline, 3 and 6 month follow up visits.
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Improvement in disease activity (as a continuous meas-
ure), controlling for baseline disease activity, will be ex-
amined in secondary effectiveness analyses. Consistent
with our goals of evaluating effectiveness rather than ef-
ficacy, persons who switch to a new biologic (i.e. non-
persistence), either for reasons of efficacy or safety, will
be considered a non-responder. As additional secondary
endpoints, DAS28 and other clinical outcomes (e.g.
Health Assessment Questionnaire, or HAQ), ACR re-
sponse, EULAR response, DAS remission, CDAI remis-
sion) at various time points also will be examined.
Allocation to specific biologic treatment is not random-
ized in CERTAIN. In order to overcome this potential
source of confounding whereby patients with certain char-
acteristics might be channeled to particular therapies, ana-
lytic adjustment will be performed to maximize the
validity of treatment comparisons by reducing confound-
ing, and improve precision. Propensity scores for receipt
of anti-TNF vs. non anti-TNF therapy will be constructed
based upon a priori and empirically-derived covariates that
will include number of prior biologic used, concomitant
MTX, concomitant glucocorticoid use/dose, duration of
RA, and reason for previous biologic discontinuation (pri-
mary vs. secondary non-response vs. safety/tolerability vs.
other). Treatment episodes for patients in the non-
overlapping distributions of the propensity score will be
trimmed (expected to be < 5% of observations removed for
this reason, based upon preliminary examination), and
multivariable adjustment will be used for the resulting
main analysis population to control for relevant confound-
ing. Numerous other potential confounders and effect
modifiers including socio-demographic, anthropometric
and disease specific characteristics will be controlled for as
needed. As one example of potentially important covari-
ates, it is possible that patients’ health insurance may
affect the selection of biologic agents initiated in CER-
TAIN, and it may not be possible to fully characterize
these payor influences on medication selection. Neverthe-
less, while this might raise concern for potential con-
founding, selection of specific biologics over another that
are dictated solely by insurance type rather than patient
characteristics may reduce confounding and bias due to
channeling. Additionally, clustering by physician practice
also will be accounted for in the analytic approach. Appro-
priate statistical techniques (e.g. mixed models, or general-
ized estimating equations) will be applied to account for
patients who contribute multiple treatment episodes to
the analysis. Based upon power calculations for the main
hypothesis to demonstrate at least a 10% difference in the
proportion of patients achieving LDA at 1 year between
anti-TNF and non anti-TNF treated patients, CERTAIN
plans to recruit approximately 2711 eligible patients over
a three-year period.
Comparative safety in CERTAIN
The Institute of Medicine (IOM) has proposed a defin-
ition for comparative effectiveness that encompasses the
domain of safety [23]. For that reason, beyond determin-
ing the comparative clinical effectiveness of various bio-
logics for controlling disease activity, it is critical to
better understand the risks of the biologics for serious
adverse events (SAEs), if any such risks differ among
Figure 1 Schematic of CERTAIN study design.
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agents, and if there are patient populations for which the
risks associated with these agents are particularly high.
Serious adverse events (SAEs) are of high interest and
are a key part of comparative safety that will be evalu-
ated within CERTAIN. Pre-specified SAEs of high inter-
est include serious infections, myocardial infarction,
stroke, malignancy, GI perforation, anaphylaxis, liver
failure, bleeding, and demyelinating events. The FDA
definition of serious adverse event also will apply (http://
www.fda.gov/safety/medwatch/howtoreport/ucm053087.
htm). Key criteria include death, hospitalization, life-
threatening event and disability or permanent damage.
Initial case ascertainment for each of these events pre-
dominantly relies on reports from physicians and pa-
tients and is obtained from the CERTAIN case report
forms. Following reporting by a physician, the CERTAIN
data coordinating center requests the site to complete a
short form to confirm the event and to obtain additional
clinical details. These confirmation forms are outcome
specific. Concurrent with the request to complete the con-
firmation form, medical records from the hospitalization
or other pertinent sources of data (e.g. pathology reports
for malignancies) are requested. Both the confirmation
form and medical records are de-identified and faxed to
the CERTAIN data coordinating center.
For each SAE, the confirmation form and associated
medical records are sent to a group of physicians who
centrally adjudicate all events according to pre-specified
criteria. These physicians are blinded to drug exposure
status to avoid bias. The classification criteria for SAE
adjudication use standardized criteria whenever possible.
For example for serious infections, the criteria system
used has been described [21]. All reported events are
classified according to their level of certainty (e.g. con-
firmed, probable, possible, unlikely).
Although medical record retrieval from the individual
CERTAIN sites is high (historically, approximately 90%),
CERTAIN has the ability to request medical records dir-
ectly from healthcare facilities. This is facilitated by the
CERTAIN investigators at University of Alabama (UAB)
functioning as an ‘honest broker’ to maintain CERTAIN
personal identifiers. Researchers at UAB therefore have
the ability to request medical records directly from hos-
pitals or physician offices. If necessary, UAB researchers
also have the ability to contact CERTAIN participants
directly to obtain updated or facility-specific medical
record release forms, thus ensuring high rates of medical
record retrieval. Through this mechanism, patients can
also be contacted (if necessary) to obtain updated med-
ical record release forms, or for other appropriate pur-
poses (e.g. conducting optional patient-targeted surveys
by email, Internet, phone, or mail). Patients consent to
both data collection and these additional features. The
study is governed by both a central institutional review
board (IRB) [the New England IRB] as well as local and
university-based IRBs if required at individual sites.
An independent mechanism to ensure completeness of
SAE case ascertainment and mortality is also available.
CERTAIN participants are consented and asked to pro-
vide identifying data that can be used to link to adminis-
trative claims databases (e.g. Medicare, commercial
insurance) and other national data sources (e.g. the Na-
tional Death Index). Approximately 40% of RA patients
in CERTAIN are anticipated to be linkable to Medicare/
Medicaid administrative claims data. Although there is
some lag in the availability of the administrative data,
the linkages between the CERTAIN clinical data and ad-
ministrative claims databases allow confirmation of the
completeness of the physician-reported SAEs. In this
way, CERTAIN has a method to externally validate the
absolute incidence rates for the various outcomes of
interest and also evaluate the generalizability of CER-
TAIN participants and their characteristics (e.g. co-
morbidities) compared to non-enrolled individuals (e.g.
other RA patients treated in geographically similar phys-
ician practices with the same health insurance) [24]. The
administrative data linkage will also allow for examin-
ation of a number of other important outcomes (e.g.
medication adherence, costs and health economics).
Genomics, genetics and comparative effectiveness
Concerns have been expressed that comparative effect-
iveness research may not be applicable to individual pa-
tients with unique genetic backgrounds [25], and a need
for bridging the “chasm” between CER and personalized
medicine has been recognized [26]. It has been posited
that both CER and genomic medicine will complement
each other as long as genome-based perspectives are in-
corporated in the design of CER studies [26].
In this context, DNA is collected at the time of the
baseline CERTAIN visit and will be used for candidate
gene and genome-wide analyses to predict response to
treatment or susceptibility to adverse events while on
treatment with biologics. The DNA collected during this
study is creating a rich genomic repository which will
allow a multitude of hypotheses to be tested with ad-
equate power and sample sizes.
Enrollment status and baseline data
CERTAIN is currently enrolling patients throughout the
U.S. As of October 7th 2013, 2234 patients had been en-
rolled. Detailed enrollment data for these participants
are available. Basic demographic, disease activity char-
acteristics and distribution of comorbities are presented
in Tables 2 and 3. Table 2 shows data for the treatment
episodes of TNF-α inhibitor experienced patients that
will be included in the primary analysis. As shown, RA
disease characteristics were generally well balanced
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between the two treatment groups. Based upon com-
parison of the standardized absolute mean difference
between anti-TNF and non anti-TNF users, the charac-
teristics that were most different included RA disease
duration (median 6 vs. 8 years), median DAS28CRP (4.7
vs. 5.0), and daily prednisone dose (5 vs. 7 mg). Most other
differences were small. For example, mean disease activity
by CDAI was comparable: 27 (anti-TNF treated) vs. 28
Table 2 CERTAIN patients who have been exposed to at least 1 TNF-α inhibitor (population used for primary comparative
effectiveness analyses)
All Anti-TNF
agents initiators
Non-anti-TNF
agents initiators
Standardized absolute
mean difference
Total, n 1321 558 763
Age (median, IQR), years 57 [47,65] 56 [47,64] 57 [48,66] 0.137
Female, n (%) 1037 (79.9) 434 (79.1) 603 (80.5) 0.036
Caucasian, n (%) 1091 (83.9) 446 (81.1) 645 (85.9) 0.129
RA disease duration (median, IQR), years 7 [3,14] 6 [3,12] 8 [4,15] 0.213
CDAI (median, IQR) 28 [21,38] 27 [20,38] 28 [21,38] 0.072
DAS28-CRP (median, IQR) 4.9 [4.2,5.6] 4.7 [4,5.4] 5.0 [4.3,5.7] 0.259
Biologic Monotherapy, n (%) 436 (33) 188 (33.7) 248 (32.5) 0.025
Concurrent DMARDs, n (%) 885 (67) 370 (66.3) 515 (67.5) 0.025
MTX only, n (%) 586 (44.4) 258 (46.2) 328 (43) 0.065
MTX dose (med, IQR) mg 20 [15,20] 20 [15,20] 20 [15,20] 0.018
MTX plus other DMARDs, n (%) 95 (7.2) 40 (7.2) 55 (7.2) 0.002
Leflunomide only, n (%) 78 (5.9) 28 (5) 50 (6.6) 0.066
Sulfasalazine only, n (%) 18 (1.4) 4 (0.7) 14 (1.8) 0.100
Hydroxychloroquine only, n (%) 53 (4) 20 (3.6) 33 (4.3) 0.038
Concomitant prednisone, n (%) 460 (34.8) 198 (35.5) 262 (34.3) 0.024
Prednisone dose (median, IQR) mg/day 5 [5,10] 5 [5,10] 7 [5,10] 0.155
No use, n (%) 877 (66.4) 363 (65.1) 514 (67.4) 0.049
Prednisone <5 mg, n (%) 53 (4) 18 (3.2) 35 (4.6) 0.070
Prednisone 5- <10 mg, n (%) 202 (15.3) 100 (17.9) 102 (13.4) 0.125
Prednisone ≥ 10 mg, n (%) 189 (14.3) 77 (13.8) 112 (14.7) 0.025
Number of prior biologics exposed to (median, IQR) 1 [1,2] 1 [1,2] 1 [1,3] 0.427
Number of prior non-biologic DMARDs exposed to (median, IQR) 2 [1,3] 2 [1,2] 2 [1,3] 0.272
Biologic started at enrollment, n (%)
Adalimumab 122 (9.2) 122 (21.9) N/A N/A
Infliximab 127 (9.6) 127 (22.8) N/A N/A
Etanercept 101 (7.6) 101 (18.1) N/A N/A
Golimumab 71 (5.4) 71 (12.7) N/A N/A
Certolizumab 137 (10.4) 137 (24.6) N/A N/A
Rituximab 125 (9.5) N/A 125 (16.4) N/A
Abatacept 334 (25.3) N/A 334 (43.8) N/A
Tocilizumab 304 (23) N/A 304 (39.8) N/A
Co-morbidities, n (%)
History of Cardiovascular disease* 104 (7.9) 42 (7.5) 62 (8.1) 0.022
History of Hypertension 333 (31.9) 144 (33.6) 189 (30.7) 0.063
History of Diabetes Mellitus 102 (10) 45 (10.8) 57 (9.5) 0.042
Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) 156 (13) 70 (13.6) 86 (12.5) 0.032
History of Malignancy (includes non -melanoma skin cancers) 100 (7.6) 41 (7.3) 59 (7.7) 0.015
Note: Standardized Absolute Mean Differences of 0.1 or less were considered clinically unimportant.
Abbreviations: IQR interquartile range, MTX methotrexate, CDAI clinical disease activity index, DAS28_CRP disease activity score with 28 joint counts and CRP
(C– reactive protein) as the inflammatory marker.
*History of cardiovascular disease included: cardiac revascularization procedures, ventricular arrhythmias, cardiac arrests, myocardial infarctions, acute coronary
syndromes, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attacks.
(Data for patients enrolled as of October 7th 2013).
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(non anti-TNF treated). Likewise, the prevalence of key
comorbidities was similar between anti-TNF and non
anti-TNF patients.
Table 3 summarizes similar information for the rest of
the enrolled population who were biologic naive. Most
of these patients (762/913, or 84%) were initiated on
Table 3 CERTAIN patients not included in the primary analysis population because they had not previously received
anti-TNF therapy at the time of initiation of a new biologic
All Anti-TNF
agents initiators
Non-anti-TNF
agents initiators
Standardized absolute
mean difference
Total, n 913 762 151
Age (median, IQR), years 56 [48,65] 55 [47,64] 60 [51,69] 0.349
Female, n (%) 675 (77.2) 563 (76.9) 112 (78.9) 0.047
Caucasian, n (%) 708 (80.8) 596 (81.2) 112 (78.9) 0.058
RA disease duration (median, IQR), years 2 [1,7] 2 [1,6] 4 [1,11] 0.294
CDAI (median, IQR) 27 [20,37] 26 [20,36] 28 [20,38] 0.115
DAS28-CRP (median, IQR) 4.8 [4.1,5.5] 4.9 [4.1,5.5] 4.6 [3.9,5.4] 0.114
Biologic Monotherapy, n (%) 221 (24.2) 178 (23.4) 43 (28.5) 0.117
Concurrent DMARDs, n (%) 692 (75.8) 584 (76.6) 108 (71.5) 0.117
MTX only, n (%) 486 (53.2) 425 (55.8) 61 (40.4) 0.311
MTX dose (med, IQR) mg/week 20 [15,20] 20 [15,20] 20 [15,20] 0.149
MTX plus other DMARDs, n (%) 95 (10.4) 81 (10.6) 14 (9.3) 0.045
Leflunomide only, n (%) 39 (4.3) 29 (3.8) 10 (6.6) 0.127
Sulfasalazine only, n (%) 13 (1.4) 10 (1.3) 3 (2) 0.053
Hydroxychloroquine only, n (%) 33 (3.6) 27 (3.5) 6 (4) 0.023
Concomitant prednisone, n (%) 287 (31.4) 243 (31.9) 44 (29.1) 0.060
Prednisone dose (median, IQR) mg 5 [5,10] 5 [5,10] 5 [5,6] 0.256
No use, n (%) 636 (69.7) 528 (69.3) 108 (71.5) 0.049
Prednisone <5 mg, n (%) 37 (4.1) 27 (3.5) 10 (6.6) 0.140
Prednisone 5- <10 mg, n (%) 134 (14.7) 111 (14.6) 23 (15.2) 0.019
Prednisone ≥ 10 mg, n (%) 106 (11.6) 96 (12.6) 10 (6.6) 0.203
Number of prior biologics exposed to (median, IQR) 0 [0,0] 0 [0,0] 0 [0,0] 0.425
Number of prior non-biologic DMARDs exposed to (median, IQR) 1 [1,2] 1 [1,2] 2 [1,2] 0.343
Biologic started at enrollment, n (%)
Adalimumab 268 (29.4) 268 (35.2) N/A N/A
Infliximab 180 (19.7) 180 (23.6) N/A N/A
Etanercept 205 (22.5) 205 (26.9) N/A N/A
Golimumab 20 (2.2) 20 (2.6) N/A N/A
Certolizumab pegol 89 (9.7) 89 (11.7) N/A N/A
Rituximab 15 (1.6) N/A 15 (9.9) N/A
Abatacept 100 (11) N/A 100 (66.2) N/A
Tocilizumab 36 (3.9) N/A 36 (23.8) N/A
Co-morbidities, n (%)
History of Cardiovascular disease* 71 (7.8) 54 (7.1) 17 (11.3) 0.145
History of Hypertension 203 (28.2) 165 (26.9) 38 (35.8) 0.194
History of Diabetes Mellitus 63 (9) 52 (8.7) 11 (11.2) 0.085
Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) 111 (13.5) 92 (13.3) 19 (14.2) 0.025
History of Malignancy (includes non -melanoma skin cancers) 54 (5.9) 45 (5.9) 9 (6) 0.002
Abbreviations: IQR interquartile range, CDAI clinical disease activity index, DAS28_CRP disease activity score with 28 joint counts and CRP (C- reactive protein) as
the inflammatory marker.
*History of cardiovascular disease included: cardiac revascularization procedures, ventricular arrhythmias, cardiac arrests, myocardial infarctions, acute coronary
syndromes, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attacks.
(Data for patients enrolled as of October 7th 2013).
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anti-TNF therapy. Patients had much earlier RA disease
duration (mean = 2 years for the overall group). As
might be expected, given that most RA treatment para-
digms have recommended initial biologic treatment to
start with anti-TNF therapy, the patients receiving non
anti-TNF medications as their first biologic were more
dissimilar to the anti-TNF users than the population
contributing to the main analysis (Table 2).
Discussion
CERTAIN is a newly-launched RA comparative effect-
iveness study examining biologic agents currently ap-
proved in the U.S. among patients with moderate or
high RA disease activity. The established infrastructure
of CORRONA is used for patient enrollment, physician
participation, collection and storage of data and man-
dates visits at regular intervals with centralized labora-
tory evaluations and a robust biospecimen repository for
RA patients initiating or switching biologic agents.
Safety data will be generated via a robust system of ser-
ious adverse event confirmation with adjudication using
medical records and linkage with external databases. En-
rollment data from the 2234 patients recruited to-date
suggest that among those who have been treated with at
least one anti-TNF therapy, characteristics of patients
initiating their next biologic were relatively well-balanced
between treatment groups. The innovative design features
of the CERTAIN study will harness the experience of an
existing network of dedicated U.S. physicians and sites to
better evaluate the comparative effectiveness of biologic
DMARDs.
Key messages
1. CERTAIN will inform effectiveness and safety
questions to compare anti-TNF to non anti-TNF
biologic agents for the treatment of rheumatoid
arthritis.
2. Innovative design elements of CERTAIN will
incorporate state of the art methods for comparative
effectiveness research.
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